ClinicalTrials.gg
CompletedNCT03033745Updated Mar 25, 2020Results posted

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

A Phase 4 interventional study of IgPro20 in Primary Immunodeficiency, sponsored by CSL Behring. Completed at 12 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.

Enrollment
Largest of 13
49 · median 25
Started
2017
the only one that year
Phase 4
4 of 14
none open now
Registered
13th of 14
by date

Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one has the largest enrollment of the 13 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 4, and was the 13th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Primary Immunodeficiency Diseases by CSL Limited as a file.
02

Study summary

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric subjects ≤ 17 years of age and at least 9 [20%] obese subjects with body mass index [BMI] of ≥30 kg/m2) with confirmed PID will be evaluated in the study. The study will include three cohorts of 15 subjects each as follows: i) Pump-Assisted Volume Cohort (weekly infusions), volume per injection site of 25 mL up to 50 mL, ii) Pump Assisted Flow Rate Cohort (weekly infusions), flow rate per injection site of 25 mL/hour up to 100 mL/hour, iii) Manual Push Flow Rate Cohort (2 to 7 infusions per week), flow rate per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute). Each cohort will test 3 infusion parameter levels (4 for the pump-assisted flow rate cohort), repeated at least 4 times over a duration of 12 weeks (16 weeks for the flow rate cohort). After 4 infusion weeks at each level, qualifying subjects (responders) will switch to the next infusion parameter level (eg, from 25 to 50 mL/h). During the study, the weekly dose will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per week range); only the respective infusion parameter under evaluation will change.

03

Conditions studied

  • Primary Immunodeficiency
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female on stable dose of IgPro20 (Hizentra) therapy.
  • Women of must be using and agree to continue using medically approved (which must be discussed with the study doctor) and must have a negative pregnancy test at screening.
  • Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or X-linked agammaglobulinemia, as defined by the Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies.
  • With infusion parameters as specified below:

Pump-Assisted Flow Rate Cohort subjects only

  • Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25 mL/h per injection site for at least 1 month prior to Day 1.

Pump-Assisted Volume Cohort subjects only

  • Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g).
  • Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25 mL/injection site for at least 1 month prior to Day 1.

Manual Push Flow Rate Cohort subjects only

  • Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site for at least 1 month prior to Day 1. The dose (volume) per injection site should not exceed 25 mL.

Exclusion criteria

Exclusion Criteria:

  • Ongoing serious bacterial infections at the time of screening.
  • Other significant medical conditions that could increase the risk to the subject.
  • Females who are pregnant, breast feeding, or planning a pregnancy during the course study.
  • Participation in a study with an Medicinal Product (IMP) other than IgPro20 within three months prior to enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    IgPro20 (Pump-Assisted Volume Cohort)

    Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.

    Drug: IgPro20

  • Experimental
    IgPro20 (Pump Assisted Flow Rate Cohort)

    Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.

    Drug: IgPro20

  • Experimental
    IgPro20 (Manual Push Flow Rate Cohort)

    Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.

    Drug: IgPro20

Interventions

  • A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.

    Also known as: Hizentra

06

What researchers measure

Primary outcomes

  1. Percentage of Responders

    A responder is a subject within the Pump-Assisted Cohorts that performs at least 3 out of 4 valid infusions at a certain infusion parameter level (weekly volumes per injection site of 25-50 mL; weekly flow rates per injection site of 25-100 mL/hour). Determination of a responder in the Manual Push Cohort is more complex due to the expected variable frequency of infusions per week (ie, 5-17) for different subjects. A responder within the Manual Push Cohort is a subject that performs a minimum number of valid infusions during 4 weeks corresponding to a certain flow rate level (\[ie, 2-7 times per week\], flow rates per injection site of 30-120 mL/hour). Valid infusions do not need to be consecutive, but each subject needs to adhere to the same schedule (number of infusions per week) throughout the study. An infusion parameter will be considered successful if at least one third (≥ 33%) of the subjects in the corresponding cohort are responders at that infusion parameter level.

    Time frame: At the end of 4 weeks for each planned infusion parameter

Secondary outcomes

  1. Rate of Treatment-emergent Adverse Events (TEAEs) Per Infusion

    Adverse event rate per infusion = number of adverse events/total number of infusions prior to subject's start date of non-response. Only events are included which start prior to subject's start date of non-response.

    Time frame: At the end of 4 weeks for each planned infusion parameter

  2. Rate of Local TEAEs Per Infusion

    Local adverse event rate per infusion = number of local adverse events/total number of infusions prior to subject's start date of non-response. Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC (Not Elsewhere Classified)", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.

    Time frame: At the end of 4 weeks for each planned infusion parameter

  3. Time to Onset of Local TEAEs

    Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.

    Time frame: At the end of 4 weeks for each planned infusion parameter

  4. Intensity of Local TEAEs

    Mild = A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate = A type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.

    Time frame: At the end of 4 weeks for each planned infusion parameter

  5. Duration of Local TEAEs

    Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions".

    Time frame: At the end of 4 weeks for each planned infusion parameter

  6. Tolerability of Infusions

    Tolerability = number of infusions without severe local adverse events / total number of infusions. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.

    Time frame: At the end of 4 weeks for each planned infusion parameter

07

Results

Posted Jan 13, 2020

Participant flow

Participant flow — Overall Study
MilestoneIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
Started151816
Completed141714
Not completed112
Withdrew: Protocol violation001
Withdrew: Adverse event101
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryPercentage of Responders

A responder is a subject within the Pump-Assisted Cohorts that performs at least 3 out of 4 valid infusions at a certain infusion parameter level (weekly volumes per injection site of 25-50 mL; weekly flow rates per injection site of 25-100 mL/hour). Determination of a responder in the Manual Push Cohort is more complex due to the expected variable frequency of infusions per week (ie, 5-17) for different subjects. A responder within the Manual Push Cohort is a subject that performs a minimum number of valid infusions during 4 weeks corresponding to a certain flow rate level (\[ie, 2-7 times per week\], flow rates per injection site of 30-120 mL/hour). Valid infusions do not need to be consecutive, but each subject needs to adhere to the same schedule (number of infusions per week) throughout the study. An infusion parameter will be considered successful if at least one third (≥ 33%) of the subjects in the corresponding cohort are responders at that infusion parameter level.

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Number · percentage of responders
Percentage of Responders
percentage of respondersIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml86.7——
40 ml73.3——
50 ml73.3——
25 ml/h—77.8—
50 ml/h—77.8—
75 ml/h—66.7—
100 ml/h—61.1—
30 ml/h——100.0
60 ml/h——100.0
120 ml/h——87.5
SecondaryRate of Treatment-emergent Adverse Events (TEAEs) Per Infusion

Adverse event rate per infusion = number of adverse events/total number of infusions prior to subject's start date of non-response. Only events are included which start prior to subject's start date of non-response.

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Number · Number of TEAEs/infusion
Rate of Treatment-emergent Adverse Events (TEAEs) Per Infusion
Number of TEAEs/infusionIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml0.183——
40 ml0.188——
50 ml0.023——
25 ml/h—0.329—
50 ml/h—0.255—
75 ml/h—0.140—
100 ml/h—0.085—
30 ml/h——0.064
60 ml/h——0.111
120 ml/h——0.081
SecondaryRate of Local TEAEs Per Infusion

Local adverse event rate per infusion = number of local adverse events/total number of infusions prior to subject's start date of non-response. Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC (Not Elsewhere Classified)", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Number · Number of local TEAEs/infusion
Rate of Local TEAEs Per Infusion
Number of local TEAEs/infusionIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml0.150——
40 ml0.063——
50 ml0.0——
25 ml/h—0.286—
50 ml/h—0.145—
75 ml/h—0.040—
100 ml/h—0.021—
30 ml/h——0.027
60 ml/h——0.082
120 ml/h——0.025
SecondaryTime to Onset of Local TEAEs

Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Mean · Days
Time to Onset of Local TEAEs
DaysIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml1.3 ± 2.45——
40 ml0 ± 0.0——
25 ml/h—1.7 ± 2.94—
50 ml/h—0.0 ± 0.04—
75 ml/h—0 ± 0.0—
100 ml/h—0 ± NA—
30 ml/h——0.2 ± 0.41
60 ml/h——0.3 ± 0.59
120 ml/h——0.2 ± 0.45
SecondaryIntensity of Local TEAEs

Mild = A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate = A type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Count of participants · Participants
Intensity of Local TEAEs
ParticipantsIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml (mild)3——
25 ml (moderate)0——
25 ml (severe)0——
40 ml (mild)1——
40 ml (moderate)0——
40 ml (severe)0——
50 ml (mild)0——
50 ml (moderate)0——
50 ml (severe)0——
25 ml/h (mild)—4—
25 ml/h (moderate)—2—
25 ml/h (severe)—0—
50 ml/h (mild)—3—
50 ml/h (moderate)—0—
50 ml/h (severe)—0—
75 ml/h (mild)—1—
75 ml/h (moderate)—0—
75 ml/h (severe)—0—
100 ml/h (mild)—0—
100 ml/h (moderate)—0—
100 ml/h (severe)—1—
30 ml/h (mild)——3
30 ml/h (moderate)——0
30 ml/h (severe)——0
60 ml/h (mild)——4
60 ml/h (moderate)——0
60 ml/h (severe)——0
120 ml/h (mild)——2
120 ml/h (moderate)——0
120 ml/h (severe)——0
SecondaryDuration of Local TEAEs

Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions".

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Mean · Days
Duration of Local TEAEs
DaysIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml2.2 ± 1.30——
40 ml2.7 ± 2.08——
25 ml/h—1.2 ± 0.37—
50 ml/h—1.6 ± 0.92—
75 ml/h—1.0 ± 0.00—
100 ml/h—1.0 ± NA—
30 ml/h——2.2 ± 2.86
60 ml/h——5.6 ± 12.91
120 ml/h——3.0 ± 2.12
SecondaryTolerability of Infusions

Tolerability = number of infusions without severe local adverse events / total number of infusions. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.

Time frame:
At the end of 4 weeks for each planned infusion parameter
Reported as:
Number · Ratio
Tolerability of Infusions
RatioIgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)
25 ml1.00——
40 ml1.00——
50 ml1.00——
25 ml/h—1.00—
50 ml/h—1.00—
75 ml/h—1.00—
100 ml/h—0.98—
30 ml/h——1.00
60 ml/h——1.00
120 ml/h——1.00

Adverse events

Collected over Up to 17 weeks per participant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20 (Pump-assisted Volume) 25 mL0/15 (0%)0/15 (0%)4/15 (26.7%)
IgPro20 (Pump-assisted Volume) 40 mL0/12 (0%)0/12 (0%)4/12 (33.3%)
IgPro20 (Pump-assisted Volume) 50 mL0/11 (0%)0/11 (0%)1/11 (9.1%)
IgPro20 (Pump-assisted Flow Rate) 25 mL/h0/18 (0%)0/18 (0%)7/18 (38.9%)
IgPro20 (Pump-assisted Flow Rate) 50 mL/h0/14 (0%)0/14 (0%)4/14 (28.6%)
IgPro20 (Pump-assisted Flow Rate) 75 mL/h0/13 (0%)0/13 (0%)3/13 (23.1%)
IgPro20 (Pump-assisted Flow Rate) 100 mL/h0/12 (0%)0/12 (0%)3/12 (25%)
IgPro20 (Manual Push Flow Rate) 30 mL/h0/16 (0%)0/16 (0%)5/16 (31.3%)
IgPro20 (Manual Push Flow Rate) 60 mL/h0/16 (0%)1/16 (6.3%)8/16 (50%)
IgPro20 (Manual Push Flow Rate) 120 mL/h0/14 (0%)0/14 (0%)7/14 (50%)
Most frequent serious events
Most frequent serious events
EventIgPro20 (Pump-assisted Volume) 25 mLIgPro20 (Pump-assisted Volume) 40 mLIgPro20 (Pump-assisted Volume) 50 mLIgPro20 (Pump-assisted Flow Rate) 25 mL/hIgPro20 (Pump-assisted Flow Rate) 50 mL/hIgPro20 (Pump-assisted Flow Rate) 75 mL/hIgPro20 (Pump-assisted Flow Rate) 100 mL/hIgPro20 (Manual Push Flow Rate) 30 mL/hIgPro20 (Manual Push Flow Rate) 60 mL/hIgPro20 (Manual Push Flow Rate) 120 mL/h
suicide attemptPsychiatric disorders0/150/120/110/180/140/130/120/161/160/14
Most frequent other events
Showing 10 of 46
Most frequent other events
EventIgPro20 (Pump-assisted Volume) 25 mLIgPro20 (Pump-assisted Volume) 40 mLIgPro20 (Pump-assisted Volume) 50 mLIgPro20 (Pump-assisted Flow Rate) 25 mL/hIgPro20 (Pump-assisted Flow Rate) 50 mL/hIgPro20 (Pump-assisted Flow Rate) 75 mL/hIgPro20 (Pump-assisted Flow Rate) 100 mL/hIgPro20 (Manual Push Flow Rate) 30 mL/hIgPro20 (Manual Push Flow Rate) 60 mL/hIgPro20 (Manual Push Flow Rate) 120 mL/h
Injection site erythemaGeneral disorders1/151/120/113/180/140/130/120/161/160/14
Injection site painGeneral disorders1/150/120/112/182/140/131/121/162/161/14
HeadacheNervous system disorders0/150/120/110/182/141/131/120/160/160/14
Upper respiratory tract infectionInfections and infestations0/150/120/110/180/140/130/120/160/162/14
DiarrhoeaGastrointestinal disorders0/150/120/110/180/140/130/122/161/160/14
NauseaGastrointestinal disorders0/150/120/110/180/140/130/122/160/160/14
Injection site swellingGeneral disorders1/150/120/112/180/140/130/121/161/161/14
Injection site pruritusGeneral disorders0/150/120/112/181/140/130/120/161/160/14
Respiratory tract infection viralInfections and infestations0/150/121/110/180/140/130/120/160/160/14
Hot flushVascular disorders0/151/120/110/180/140/130/120/160/160/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)Total
<=18 years011112
Between 18 and 65 years1451433
>=65 years1214
Age, Continuous
Age, Continuous(years)IgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)Total
Mean49.1 ± 14.1826.7 ± 24.5247.9 ± 13.2840.5 ± 20.97
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)Total
Female9101029
Male68620
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)Total
American Indian or Alaska Native0101
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White14161242
More than one race1023
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)IgPro20 (Pump-Assisted Volume Cohort)IgPro20 (Pump Assisted Flow Rate Cohort)IgPro20 (Manual Push Flow Rate Cohort)Total
Canada3069
United States12181040
08

Study locations

12 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35209, United States
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • University of Southern Florida
    Saint Petersburg, Florida 33701, United States
  • Georgia Pollens Clinical Research Centers
    Albany, Georgia 31707, United States
  • Long Island Jewish Medical Center
    Great Neck, New York 11021, United States
  • Icahn Medical Institute
    New York, New York 10029, United States
  • Center for Clinical Research Rochester General Hospital
    Rochester, New York 14607, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Duke University School of Medicine
    Durham, North Carolina 27705, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • McGill University
    Montréal, Quebec H4A3J1, Canada
09

References and documents

Publications

  • Anderson JT, Bonagura VR, Cowan J, Hsu C, Mustafa SS, Patel NC, Routes JM, Sriaroon P, Vinh DC, Hofmann JH, Praus M, Rojavin MA. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study. J Clin Immunol. 2021 Feb;41(2):458-469. doi: 10.1007/s10875-020-00912-5. Epub 2021 Jan 6. PubMed 33409867 ↗
  • Cowan J, Bonagura VR, Lugar PL, Maglione PJ, Patel NC, Vinh DC, Hofmann JH, Praus M, Rojavin MA. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study. J Clin Immunol. 2021 Jan;41(1):66-75. doi: 10.1007/s10875-020-00876-6. Epub 2020 Oct 6. PubMed 33025378 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Dec 2018, 22 months.

Results were first posted in Jan 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Jan 27, 2017
StartActual
Feb 1, 2017
Primary completionActual
Dec 14, 2018
CompletionActual
Dec 14, 2018
Results first posted
Jan 13, 2020
Last update
Mar 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03033745
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jan 27, 2017
Start date
Feb 1, 2017
Primary completion
Dec 14, 2018
Completion
Dec 14, 2018
Results posted
Jan 13, 2020
Last update
Mar 25, 2020

Study contacts

Study Physician
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hizentra

Start the discussion